Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance
With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...
Finanical Reports
Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance
US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...
Zai Lab Reports Strong Revenue Growth in 2022 Interim Results
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has released its 2022 interim...
Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results
China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24...
Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges
China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85...
SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results
SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private...
YiChang HEC Reports Strong Recovery in 2022 Interim Results
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,...
Sino Biopharmaceutical Reports Mixed Results in 2022 Interim Report
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has released its 2022 interim report, recording revenues of...
China Resources Pharma Reports Strong Interim Results Amid COVID-19
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for...
Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...
China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth
A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...
GenScript Biotech’s H1 2022 Revenue Rises 32.7% on Carvykti CAR-T Sales
Nanjing-based GenScript Biotech, a biopharma and contract research firm, reported a 32.7% year-on-year (YOY) revenue...
Simcere Pharma’s H1 2022 Revenue Rises 27% on New Drug Sales, R&D Push
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in...
Alphamab Oncology Reports H1 2022 Revenue Growth Driven by Envafolimab Commercialization
China-based Alphamab Oncology (HKG: 9966) reported RMB 53.57 million (USD 7.7 million) in H1 2022...
RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales
China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for...
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05...
MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results
China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022,...
Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion)...
Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months...